
# **∧**manat

Invest . Grow . Impact



# **Dis**

## **Disclaimer**

#### **Important Information**

Upon receipt of this Earnings' Presentation, the accompanying Press Release to Invest, or any oral presentation relating thereto (collectively, the "Information"), and confirmation of subscription to the Offer Shares, you irrevocably agree to be bound by the following terms and conditions:

The Information is confidential and may not be reproduced, redistributed, published or passed on to any other person, directly or indirectly, in whole or in part, for any purpose. If you were not meant to receive the Information or received it illegally by any third party's breach of the aforementioned confidentiality undertaking, you must immediately return it to its owner - that is Amanat Holdings PJSC (the "Company").

The Information is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of, or located in, any locality, state, country or other jurisdiction where such distribution or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.

The Information has not been reviewed, verified, approved and/or licensed by the Central Bank of the United Arab Emirates ("UAE"), Securities and Commodities Authority of the UAE and/or any other relevant licensing or regulatory authority in the UAE including any licensing authority incorporated under the laws and regulations of any of the free zones established and operating in the territory of the UAE, notably the Dubai Financial Services Authority ("DFSA").

The Information does not constitute a recommendation regarding the offering of the Offer Shares. Prospective investors are required to make their own independent investigations and appraisals of the business and financial condition of the Company and the nature of the Offer Shares before taking any investment decision with respect thereto. If you do not understand the contents of the Information, you should consult an authorized financial adviser.

Subject to applicable law in the UAE, the Company shall not accept any responsibility whatsoever in relation to the Information and makes no representation or warranty, express or implied, for the contents of the Information, including its accuracy, completeness or verification or for any other statement made or purported to be made in connection with the Company, and nothing in the Information, or this Disclaimer, shall be relied upon as a promise or representation in this respect, whether as to the past, the present, or the future. The Information contains forward-looking statements, including the Company's target return on investment. These statements and any other statements that are not historical fact that are included in the Information are forward-looking statements. Forward-looking statements give the Company's current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the Company's actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which it will operate in the future.

The Information has not been independently verified and will not be updated. The Information, including but not limited to forward-looking statements, applies only as of the date of this Earnings' Presentation and is not intended to give any assurances as to future results. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to the Information, including any financial data or forward-looking statements, and will not publicly release any revisions it may make to the Information that may result from any change in the Company's expectations, any change in events, conditions or circumstances on which these forward-looking statements are based, or other events or circumstances arising after the date of this document. Market data used in the Information not attributed to a specific source are estimates of the Company and have not been independently verified.

## **Table of Contents**

02 03 01 **Company Overview** Q1 - 2023 Results Q1 - 2023 Key Highlights & pg. 4 pg. 9 pg. 14 Outlook 06 05 04 **Appendices** pg. 37 **Appendices Appendices** pg. 28 pg. 20 • Investment Proposition • Education Platform Update Healthcare Platform Leadership Team Update Analyst Coverage • Other Financial Information



## Amanat | A unique, resilient investment proposition

The only publicly listed, Sharia'-compliant healthcare and education investment company in GCC

Permanent capital vehicle generating private equity like returns

23<sup>(1)</sup> transactions concluded to date, with 4 concluded in 2022

Portfolio of market leading assets in the MENA Healthcare and Education sectors

Defensive and resilient sectors enabling superior risk adjusted returns with an industry Beta of <1

Cash flow generating assets with attractive growth prospects

Circa AED 2.7 billion in AUM in addition to AED 0.7 billion of cash, with incremental debt capacity for deployment

## Highly supportive market fundamentals


Operate in defensive yet growing sectors with active market fundamentals and supportive demographics


#### ESG, a core pillar of strategy

Integrating positive social change and climate action directly into the overall business strategy

#### **Attractive dividend policy**


Guided dividend distribution range of at least 40% of full year profit attributable to equity holders






## Amanat | A portfolio of market leading companies


Established portfolio of **nine market-leading Healthcare and Education investments** in UAE, KSA and Bahrain that generate stable cashflows and have significant growth prospects



## Amanat | AED 2.7 billion in AUM and AED 0.7 billion of cash



## Amanat | **Delivering results**






## Q1 - 2023 Key Highlights & Outlook

Amanat continues to deliver on the strategy announced in 2020, with continued growth in profitability in Q1-2023




- Amanat Healthcare created to consolidate Amanat's world class portfolio of healthcare assets.
   Further value creation opportunities being explored including inorganic and organic growth opportunities
- Completion of the merger between CMRC and Sukoon, establishing the largest pan-GCC post-acute care platform with a goal of operating c.1,000 beds in three years
- Shareholder approval for a buyback of up to 5% of outstanding shares and dividend payout of AED 100 million





## Underlying Earnings Growth

- 27% growth in adjusted total income
- 24% growth in Adjusted Net Profit
- Healthcare platform: 30% earnings growth YoY to AED 18.0 MN in Q1-2023
- Education platform: 23% earnings growth YoY to AED 40.3 MN in Q1-2023





## 2023 Outlook

- Exploring potential monetization opportunities for Amanat Healthcare in the near term, which may include a regional IPO
- Special Education (SEN) Growth: Continued expansion of day care centers and schools to cater to the growing demand in KSA
- K-12 Market Entry in KSA and UAE: Explore initial entry through acquisitions, followed by potential greenfield expansions to capitalize on regional education opportunities



## CMRC & Sukoon I The largest PAC platform in the GCC region

#### **PAC Value Proposition**



#### Reduce cost of healthcare

30% - 70% lower than the cost in acute care hospitals



#### Improve patient access and quality of life

Provide a comprehensive and continuous patient journey



## Improve Healthcare Sector Efficiency


Unblock beds within acute care facilities

#### Sukoon & CMRC Merger supports delivering on:

#### **Amanat's Corporate Strategy**

- · Own controlling majority stakes
- Drive operational performance
- Deliver on bed expansion
- Consolidate portfolio companies into platforms

#### **Shareholder Value Creation**




- Expanding revenue by introducing unique inpatient and outpatient offerings
- Enacting an efficient re-organization
- Benefiting from cost efficiencies and economies
- Creating immediate mass
- · Immediate market entry

## POST COMPLETION STRUCTURE Amanat consolidates its current and future PAC platform starting with the merger of Sukoon & CMRC PAC Platform(1) Amanat Sukoon Shareholders 51%+ 100% 82% Abu Dhabi. New Hospitals Al Ain & Dhahran (KSA & Rest of GCC) **GROWTH PROSPECTS**


Amanat's PAC Platform is expected to consist of c. 1,000 LTC beds across multiple cities in the GCC within 3 years



# Healthcare Growth Strategy | Targeting 1,000 post acute care beds in three years



# Education Growth Strategy | **Asset light expansion across the GCC** with further investment planned into K-12





## Financial Highlights | Earnings growth

Net Profit (1) Adjusted Net Profit (1) (2) Total Income<sup>(1)</sup> Q1-2023 Q1-2023 Q1-2023 **AED 59.9** MN AED 39.7 MN AED 40.1 MN vs AED 47.0 MN in Q1-22 (+27%) vs AED 32.0 MN in Q1-22 (+24%) vs AED 32.3 MN in Q1-22 (+24%) Total Income | AED MN Adjusted Net Profit | AED MN Net Profit | AED MN 280.8 371.0 117.4 103.4 181.8 114.2 32.3 40.1 111.7 42.0 47.0 59.9 60.0 26.0 23.1 31.5 32.0 39.7 14.6 10.1

Q1 2023

Key Highlights

24% growth in adjusted net profit

27% growth in total income

# Healthcare platform earnings growth:

income up 30% YoY to AED 18.0 MN; primarily driven by the ramp up of CMRC KSA

## Education platform earnings growth:

income up 23% YoY to AED 40.3 MN; impact of HDC acquisition and growth at MDX offset by the impact of launch of Edtech venture and higher finance costs at NEMA

FY19 FY20 FY21 FY22 Q120 Q121 Q122 Q123

FY19 FY20 FY21 FY22 Q120 Q121 Q122 Q123

FY19 FY20 FY21 FY22 Q120 Q121 Q122 Q123


<sup>(1)</sup> Total Income and Net Profit include the share of income from subsidiaries & associates and finance lease income from NLCS, after PPA, excluding NCI. (2) Adjusted Net Profit excludes the gain on disposal and trading results from divested entities, one off non-recurring gains or losses, and transaction costs.



## Healthcare | 30% YoY growth in earnings

Enhancing Portfolio Value			
Value Creation	Growth Plan		
✓ CMRC KSA: delivers 50% revenue growth YoY and positive EBITDA vs. losses in Q1-22	✓ CMRC: ongoing expansion of 150 beds in KSA and 20 beds in UAE. Post-completion CMRC capacity will be over 400 beds		
✓ Sukoon: profit realized after 3 years of consecutive losses following execution of turnaround strategy	√ Sukoon: 100 bed expansion due for completion in Q2-2024 post which bed capacity will reach over 200 beds		
✓ Malaki Specialist Hospital: core revenue increase of 13% in Q1- 23 following rebranding and market repositioning initiatives	✓ Malaki Specialist Hospital: approval obtained in Q4-22 to expand services to male patients; launch of additional outpatient clinics		

## Healthcare Platform Income<sup>(1&2)</sup> | AED MN



- 30% earnings growth YoY to AED 18.0 MN in Q1-23
- 23% increase in CMRC income to AED 19.4 MN driven by ramp up and profitability of CMRC KSA and stable contribution from CMRC UAE
- Increasing positive contribution from Sukoon (AED 0.5 MN vs. AED 0.3 MN in Q1 of the prior year)

**5**Specialised Hospitals

418
Operational beds


**270**Beds under development

<sup>(1)</sup> Platform income excludes PPA amortization and gain and trading results from divested entities (2) Finance charges in relation to Malaki Specialist Hospital have been reclassified from platform income to finance charges in the prior year.



Enhancing Portfolio Value			
Value Creation	Growth Plan		
<ul> <li>✓ MDX Dubai: recognized as the largest private university in Dubai for 2 consecutive years by KHDA</li> <li>✓ MDX Dubai: over 4,500 students up from 2,900 at acquisition</li> <li>✓ NEMA: maintained the largest share of the Abu Dhabi private Higher Education market, with a presence across 6 campuses</li> <li>✓ Enhanced online learning and digitization across portfolio</li> <li>✓ HDC: #1 provider of special education and care in KSA; c. 4,000 beneficiaries across 10 schools and 24 daycare centers</li> </ul>	<ul> <li>✓ MDX Dubai opens 2<sup>nd</sup> campus in another academic hub</li> <li>✓ Abu Dhabi University (subsidiary of NEMA) launches new campus in Al Ain</li> <li>✓ NEMA: acquires 100% of LCT in May 2022</li> <li>✓ NEMA: acquires remaining KHC minority stake in 2021</li> <li>✓ HDC: expansions in progress to add centers in KSA whilst concurrently exploring regional expansion opportunities</li> </ul>		

## Education Platform Income (1) | AED MN



- Earnings growth of 23% YoY to AED 40.3 MN
- HDC: Net Income for Q1 2023 is SAR 10.3 MN, driven by the opening of new centers and schools and the ramp-up of newly opened facilities
- MDX Dubai: income increased by 16% supported by strong revenue growth (14%) attributable to a 13% YoY increase in students enrolled
- NEMA Holding: Q1 2023 income declined due to launch of the new EdTech venture and higher finance costs

18k Student and Beneficiaries Population

5 Abu Dhabi Campuses **3**Dubai
Campuses



## Financial Summary | Earnings growth

AED MN	1Q - 22	1Q - 23	Change	Key Highlights
Total Income	47.0	59.9	27%	Higher holding level costs (AED 1 MN)
Adjustments	0.0	(0.3)		Impact of hires during 2022 and higher professional fees
Adjusted Total Income <sup>(1)</sup>	47.0	59.5	27%	
Platform and Other Income				Higher financing costs (AED 3.6 MN)
Education	32.7	40.3	23%	Increase in interest rates on existing bank financing arrangements
Healthcare	13.9	18.0	30%	urungenienis
Purchase Price Amortization	(2.9)	(3.5)	(22)%	
Interest & Other Income	3.3	4.7	44%	Higher Transaction Costs (AED 0.3 MN) Increased deployment activity related to PAC merger
Holding Level Costs	(11.1)	(12.2)	(10)%	transaction
Transaction Related Costs	(0.1)	(0.4)	(100)%	
Transaction Related Costs (associates)	(0.2)	0.0	100%	Higher Interest and Other Income (AED 1.4 MM)
Finance Charges	(3.6)	(7.2)	(100)%	Higher Interest and Other Income (AED 1.4 MN)
Non-Recurring Expense	0.0	(0.4)	(100)%	Higher interest rates secured on fixed deposits
Net Profit	32.0	39.7	24%	
Adjusted Net Profit <sup>(1)</sup>	32.3	40.1	24%	
AED	FY 22	1Q - 23	Change	
AUM (BN)	2.7	2.7	2%	Strong balance sheet and liquidity with low leverage
Cash (MN) <sup>(2)</sup>	584	654	12%	AED 654 MN of cash, AED470 MN at an Amanat
Leverage (MN)	438	435	1%	Holdings level. AED 100 MN dividends paid post period
Net Cash <sup>(3)</sup> (MN)	146	219	49%	• 15% leverage
Leverage % <sup>(4)</sup>	15%	15%	0%	Current period increase in cash balances mainly due
Share Price (AED)	0.85	0.96	13%	to post year-end receivable collections and positive
Market Capitalisation (BN)	2.1	2.4	13%	working capital movements across the Group

<sup>(1)</sup> For a reconciliation of adjusted measures please refer to other financial information;

<sup>(2)</sup> Cash balances include the cash balances of Amanat Holdings PJSC and its subsidiaries;

<sup>(3)</sup> Net cash excludes lease liabilities;

<sup>(4)</sup> Leverage calculated as debt / debt + paid up capital.







## Healthcare Platform | CMRC



## Post-Acute Care, Long-Term Care & Rehabilitation

Cambridge Medical and Rehabilitation Centre ("CMRC") is a provider of specialized rehabilitation and long-term care, with facilities in Abu Dhabi and Al Ain in the UAE, and Dhahran in Saudi Arabia

CMRC provides multidisciplinary and intensive rehabilitation for individuals suffering from a range of medical conditions such as strokes, brain or spinal cord injuries, or congenital conditions including cerebral palsy

- Specialized healthcare provider offering best-in-class capabilities and clinical quality in post-acute care services including long-term care, rehabilitation (in-patient and outpatient) and homecare
- Large supply and demand gap in the GCC estimated at c. 2k and c.15k beds in the UAE and KSA respectively
- Proven, cohesive and experienced top management team

Action Plan	✓ Completed Initiative	Ongoing Initiative
Corporate Strategy	<ul> <li>✓ Achieve Patient Satisfaction Score of 90%</li> <li>150 bed expansion underway in Al Khobar, KSA</li> <li>① Expand in UAE from the existing base into Dubai and/or the Northern Emirates</li> <li>② Al Ain facility onsite expansion to add additional 13 inpatient beds and outpatient capacity</li> <li>④ Abu Dhabi facility outpatient clinics are being relocated to off-site villa which will create 7 beds</li> <li>① Launch new services (e.g., Sports Medicine, Orthopedic Surgery, etc)</li> </ul>	
Corporate Finance	<ul> <li>Evaluate optimal capital structure and funding options for expansion plans</li> <li>Approve Delegation of Authority</li> <li>Develop financial and operational KPIs to track Management performance</li> </ul>	
Corporate Governance		




## Healthcare Platform | CMRC



#### Financial Performance | Quarter Ended 31st March 2023

- 23% Increase in consolidated group profitability in Q1-23 vs. Q1-22 on the back of Dhahran facility ramp-up and stable UAE business performance
- Dhahran facility realised significant patient ramp-up reaching c. 94% occupancy in Q1-23 vs 70% in Q1-22 and delivering EBITDA positive from April 2022 and overall net profit of AED 0.3 MN for the quarter
- · Delivering on KSA growth story through the development of a new 150-bed inpatient facility in Eastern Province, KSA
- In the UAE, an onsite expansion in Al Ain of 13 beds to add additional inpatient and outpatient capacity is underway, in addition to 7 beds in Abu Dhabi





## Healthcare Platform | Sukoon



## Post-Acute Care, Long-Term Care & Rehabilitation

Sukoon International Holding Company ("Sukoon") provides post acute extended care and critical care medical services to patients who are no longer suited for care within a traditional hospital setting

International Extended Care Center ("IECC"), Sukoon's flagship JCI-accredited facility located in Jeddah, has a current capacity of 130 beds and an increase in physical capacity to up to 230 beds is underway

- Specialized healthcare provider offering best-in-class capabilities and clinical quality in post-acute care services including long term care and ICU
- Large supply and demand gap in KSA at c. 15k beds
- Attractive market segment with strong market fundamentals conducive to growth, supported by an ageing population, increased life expectancy and prevalence of chronic disease
- Market leader in the Western Province of KSA

Action Plan	✓ Completed Initiative	⊙ Ongoing Initiative	
Corporate Strategy	Complete facility redesign and renovation to improve patient flow and increase capacity Complete Phase 1 of facility renovation Introduce new service lines such as homecare Diversify client base and contract with new payors		
Corporate Finance	<ul> <li>Fund facility renovation and growth plans from available cash and internally generated funds, explore additional sources of funding as required</li> <li>Maintain JCI accreditation</li> <li>Maintain CBAHI accreditation</li> <li>Develop financial and operational KPIs to track Management performance</li> </ul>		
Corporate Governance			



## Healthcare Platform | Sukoon



## Financial Performance | Quarter Ended 31st March 2023

- Implementation of cost optimization initiatives proved successful with Sukoon generating EBITDA of SAR 4.0 MN in Q1-23 vs. SAR 2.7 MN in Q1-22 with EBITDA margins improving to c. 20% (vs. 13% in Q1-22)
- Facility renovation works to expand bed capacity by c. 100 beds activated and strong patient pipeline to be realized in remainder of the year





## Healthcare Platform | Al Malaki Specialist Hospital



#### **Acute Care**

Al Malaki Specialist Hospital (previously known as the Royal Hospital for Women & Children) is a premium multispecialty hospital located in the Kingdom of Bahrain

Al Malaki provides end-to-end holistic quality care including obstetrics & gynecology, orthopedics, internal medicine, ENT, gastroenterology, dermatology & cosmetology, physiotherapy, dentistry, and pediatrics services

The facility launched its operations in March 2019

- Multi-specialty provider covering the entire family including with established Centers of Excellence in the fields of obstetrics & gynecology and pediatric services
- State-of-the-art infrastructure located on a sizable land plot with potential for future expansion opportunities
- Strong local strategic partners aligned on execution and capabilities to fund growth plans
- Located in an affluent area of Bahrain with limited competition in the catchment area

Action Plan	✓ Completed Initiative	① Ongoing Initiative
Corporate Strategy	<ul> <li>✓ Launch of the Cosmetology and Bariatrics departments</li> <li>✓ Establish in-house laboratory service to improve lab referral vol</li> <li>✓ Launch "Pediatric Centre of Excellence"</li> <li>✓ Modify business activity to "General Hospital" to allowing for ma</li> <li>✓ Repurpose existing space to allow addition of at least +7 OP co</li> </ul>	ale patients to be cared for at Al Malaki
Corporate Finance	• Improve Working Capital Cycle	
Corporate Governance	<ul> <li>✓ Hire an independent management team to drive the Company</li> <li>✓ Develop financial and operational KPIs to track Management pe</li> <li>✓ Obtain National Healthcare Regulatory Authority Accreditation</li> </ul>	




## Healthcare Platform | Al Malaki Specialist Hospital



#### Financial Performance | Quarter Ended 31st March 2023

- 13% growth in core revenue year-on-year (excluding impact of COVID nursing contract that expired in Q1-22),
- Core revenue driven by:
  - o Ramp-up in IVF and OBG specialties
  - o Onboarding of Star Doctor in Cosmetology
  - Partnership with Saudi Medical Tourism Agency coupled with securing reimbursement coverage from a leading Saudi Insurance provider to help drive patient footfall from the KSA





## Healthcare Platform | CMRC Real Estate



#### **Real Estate**

The property leased by CMRC Abu Dhabi comprises c. 6,000 square meters of land and a built-up area of c. 6,600 square meters encompassing 2 three-leveled building blocks with 106 inpatient licensed beds alongside rehabilitation facilities including 14 outpatient rooms, 3 gyms, a hydrotherapy pool and a series of other amenities.



- The transaction marks Amanat's first investment in healthcare real estate;
- The acquisition is in line with Amanat's strategy to invest in Social Infrastructure where there are synergies with portfolio companies
- Serves as an enabler for the growth of Amanat's portfolio companies; and
- Generates a resilient, consistent, and steady yield.







## Education Platform | **NEMA Holding**



## **University, Post-Graduate and Vocational**

NEMA Holding ("NEMA") is a leading educational group operating in Abu Dhabi, Al Ain and Dubai, with a 20-year track record in the market. The group currently enrolls c. 9,000 students, with an offering spanning higher education, vocational and corporate training sectors. NEMA's mission is to become the leading platform in the Arab world for higher education and learning solutions, continuing to develop the education sector in the UAE, attracting international students and ensuring a qualified workforce for sustainable economic growth.

- Largest market share among private players in the emirate of Abu Dhabi;
- Differentiated offering vs. other Abu Dhabi based private universities, with a vast and high-quality portfolio of job-relevant programs;
- Diversified revenue base (higher education, vocational and corporate training) as well as substantial infrastructure and land bank to support future growth; and
- Catering to different price points within the market through Abu Dhabi University, Liwa College of Technology and Khawarizmi International College.

Action Plan	✓ Completed Initiative	① Ongoing Initiative	
Corporate Strategy	<ul> <li>✓ Acquired 100% interest in Liwa College of Technology (formerly Emirates College of Technology), one of the leading and most established players in the higher education space in Abu Dhabi</li> <li>✓ Acquired remaining 49% stake of Khawarizmi Holding Company to reach 100% ownership</li> <li>⑤ Implementing a new tech-based offering at the Knowledge Group, catering to the growing demand for digital learning solutions</li> <li>⑥ Screening additional suitable acquisition targets</li> <li>⑥ Introducing new programs/courses in line with market needs</li> </ul>		
Corporate Finance	<ul> <li>✓ Implemented cash management initiatives to reduce finance expenses</li> <li>✓ Optimized capital structure to fund growth initiatives and improve cost and maturity profile of debt</li> </ul>		
Corporate Governance	<ul> <li>✓ Implemented a revised legal structure for the group</li> <li>✓ ADU achieved a top 350 ranking among universities globally and t</li> <li>⑤ Focusing on obtaining further academic excellence and recognitio</li> <li>⑥ Optimizing organizational structure and human capital</li> </ul>	,	

## Education Platform | NEMA Holding



## Financial Performance | Quarter Ended 31st March 2023\*

- Revenue is 5% higher YoY due to consolidation of LCT, partially offsetting lower training revenues and a decline in credit hours sold at ADU
- Profit margin were lower due to launch of the EdTech venture and negative operating leverage; Net Profit is further impacted by higher finance costs



<sup>(\*)</sup> NEMA's fiscal year ends on 31 August; results are presented based on Amanat's first quarter, ending 31 March.

<sup>(1)</sup> Net Debt/Cash excluding lease liabilities of AED 85.2 MN.

<sup>(2)</sup> Grant income of AED 3.5 MN is included in EBITDA and Net Profit.



## Education Platform | Middlesex University Dubai



## **University and Post-Graduate**

Middlesex University Dubai was established in 2005 as the first overseas campus of the internationally renowned Middlesex University in London. Middlesex has a diverse student body of c. 4,500 students across two campuses providing students from across the GCC and beyond the opportunity to obtain a top-quality UK degree, which uses the same validation and monitoring system as the London campus, while living in the heart of Dubai.

- Unique value proposition of offering high quality education and a leading UK degree at an affordable price point;
- Demonstrated ability to outperform enrolment growth vs. main competitors and overall market;
- Robust financial profile coupled with a cash generative and negative working capital business model; and
- Institutionalized corporate structure, internal controls and governance.

Action Plan	✓ Completed Initiative	① Ongoing Initiative	
Corporate Strategy	<ul> <li>✓ Achieved 13% a YoY student growth, despite a very competitive Dubai higher education market</li> <li>✓ Largest KHDA regulated institution for student enrolments for 2 years in a row (AY 2020-21 and AY 2021-22)</li> <li>✓ Awarded a 5-star rating from the KHDA</li> <li>✓ Launched a second campus in Dubai International Academic City in Sep 2021</li> <li>✓ Launched the Centre for Continuing Education, offering English language and short courses, professional qualifications and study camps</li> <li>⊙ Introducing new programs in line with market needs</li> <li>⊙ Enhancing scope and effectiveness of international recruitment campaigns, in both core and new geographies</li> <li>⊙ Continuing assessment of international expansion options as well as domestic business development opportunities to increase market share</li> </ul>		
Corporate Finance	✓ Distributed AED 100 MN dividends over the past 2 years (AED 36 MN in Jun 2020, AED 32 MN in Feb 2021 and AED 32 Mar 2022)  ⊙ Optimizing capital structure to fund growth initiatives		
Corporate Governance	<ul> <li>Reviewing organization structure design</li> <li>Enhancing internal systems through technology and automation and better planning around resources</li> </ul>	n, allowing for an increased speed and accuracy of information	



## Education Platform | Middlesex University Dubai



#### Financial Performance | Quarter Ended 31st March 2023(\*)

- Revenue up 14% YoY, due to 13% growth in students, thanks to record AY 2022/2023 intakes demonstrating continued consolidation of the domestic market and solid growth in the international student base
- EBITDA and Net Profit are 13% and 16% higher YoY, respectively, in line with top line growth and supported by cost discipline



<sup>(\*)</sup> The university's fiscal year ends on 31 August; results are presented based on Amanat's first quarter, ending 31 March. (1) Net Debt/Cash excluding lease liabilities of AED 45.3 MN.



## Education Platform | Human Development Company



## **Special Education and Care Services**

Human Development Company ("HDC") was established in 2007 and grew to become the leading provider of Special Education and Care ("SEC") services in KSA. HDC caters to c. 4,000 beneficiaries through a network of 24 daycare centers, 10 schools, and specialized rehabilitation medical clinics, across 6 provinces in KSA. HDC is renowned for its commitment to providing high quality services, with its daycare centers typically rated A+ by the Ministry of Human Resources and Social Development ("MHRSD") in KSA.

- Market leader in an underserved sector with strong underlying growth drivers
- Strengthens both Amanat's healthcare and education platforms
- Scalable business through a tech-enabled standardized approach to service delivery and asset light operating model
- Clear growth strategy:
  - o Opening new branches in Saudi Arabia;
  - o Introduction of new service lines; and
  - o Potential footprint expansion to wider GCC region
- Opportunity for Amanat to enhance quality and access in a sector that caters to a vulnerable segment of the population

	Action Plan	✓ Completed Initiative	① Ongoing Initiative	
	Corporate Strategy	<ul> <li>✓ Developed a strategy for organic and inorganic expansion in KSA</li> <li>✓ Launched 2 new centers in Q1 2023</li> <li>⊙ Exploring and assessing opportunities for expansion across the GCC</li> <li>⊙ Exploring potential partnerships for the introduction of new service lines</li> <li>⊙ Improving HDC's brand awareness and investing in marketing and advertising</li> </ul>		
1	Corporate Finance	<ul> <li>Evaluating and enhancing financial reporting systems, policies and capabilities</li> <li>Assessing the optimal capital structure to fund the growth and maximize shareholders' return</li> </ul>		
	Corporate Governance	<ul> <li>Reviewing and strengthening standard operating policies and p</li> <li>Identifying key requirements for systems and IT infrastructure</li> <li>Reviewing and proposing enhancements to organization structure</li> </ul>		



## Education Platform | Human Development Company



## Financial Performance | Quarter Ended 31st March 2023

- c. 4,000 Beneficiaries as of March 2023, a growth of 40% YoY
- Expansions in progress that will add additional centers and schools in KSA whilst concurrently exploring regional expansion opportunities
- Revenue for Q1 2023 is SAR 44.3 MN with EBITDA of SAR 21.4 MN (48% margin)
- Net profit for Q1 2023 is SAR 17.1 MN





## Education Platform | NLCS Real Estate



#### **Real Estate**

Amanat owns the real estate assets of North London Collegiate School Dubai ("NLCS"). NLCS was established in 2018, as a premium International Baccalaureate curriculum K-12 school and is one of the top schools in the UK in terms of academic results in the International Baccalaureate for twelve consecutive years. The campus, located in Dubai has a total land area of 38,217 sqm and a built-up area of 41,143 sqm. During the past 5 years, NLCS has significantly ramped-up student numbers to over 1,300 in AY 2022/23. Amanat leases the assets to the operator under a finance lease arrangement.

- Diversify Amanat's education investment portfolio into the social infrastructure space;
- A stable asset class generating attractive yields and long-term recurring income;
- A premier UK education provider with solid academic affiliations and potential to expand and grow the campus; and
- Attractive catchment area with growing population and conducive demographics.





## Е

## Education Platform | BEGIN

# BEGIN

## **Venture Capital**

Amanat invested in the Series C funding round of BEGiN, a US-based, award-winning, early education technology company. BEGiN's investors and partners include some of the most recognized children's brands including Sesame Workshop, LEGO Ventures, Gymboree Play & Music and Fisher-Price. BEGiN's flagship brand is HOMER, the essential proprietary learning framework for young children. The HOMER Method delivers academic skills like literacy and math, in addition to personal skills like problem solving and social emotional awareness through content that is personalized to kids' interests, age and learning level. BEGiN has further expanded its product portfolio through the acquired Little Passports (physical subscription kits for kids aged 3-10), codeSpark (learn-to-code program for kids) and KidPass (marketplace for in-person and online classes and tutoring).




- Diversify Amanat's education investment portfolio into EdTech;
- Potential for expansion in the MENA region, with Amanat acting as the strategic partner;
- Talented and experienced; with a proven track record of building highly successful businesses;
- Provides effective research-based products with high quality content developed from top industry experts based on existing and proprietary pedagogy research with proven results of engagement and efficacy; and
- Partnerships with renowned global household players.





## Amanat Portfolio | Healthcare & Education platforms summary



<sup>(1)</sup> Including maximum contingent consideration of AED 46.6 MN.

<sup>(2)</sup> Announced on 20th December 2022 and completed on 14th April 2023. Ownership interests reflect effective ownership with final ownership subject to completion mechanics. As of 31 March 2023, Amanat's effective ownership interest was 100% in CMRC and 33.25% in Sukoon.



## Amanat's Strategy | Invest, Grow, Impact

Bringing together best-in-class deal sourcing and portfolio optimization expertise to capture growth opportunities in the MENA healthcare and education sectors

Invest in healthcare and education

Establish platforms

Grow earnings and ROI

Deliver sustainable dividend

Drive innovation through EdTech and HealthTech

1

### **Identify and Invest**

Identify cash flow generating assets in healthcare and education that have significant growth opportunities and high quality management teams

Active deal sourcing supported by deep sector expertise uniquely positions Amanat to identify quality assets in the sector

Established market presence and unique social infrastructure specialization enables unparalleled visibility on deal pipeline

2

### Pursue growth and scale

Establish platforms by developing and executing strategic growth opportunities, to scale business, enhance income generation and maximise value creation

Strong track record of developing and executing organic and inorganic strategic growth opportunities

Expertise in capital structure optimisation and corporate governance implementation; enables additional value creation at portfolio companies

3

## Optimize valuation

Continue to hold investments for growth and income generation or explore exit opportunities to realise value

Track record of improving income generation capabilities, enabling sustainable and attractive dividends

Three successful exits to date generating superior returns in excess of market

## 1. Identify and invest in high quality, defensive assets

Strong balance sheet with significant cash to deploy on value generating opportunities in the healthcare and education sectors, supported by access to competitive debt financing

### **IDENTIFY**

Extensive visibility on regional deal pipeline

Source active and passive opportunities

Executed 23 transactions valued at c. AED 5.3 BN

## **INVEST**

**AED** 

654<sub>MN</sub>

Cash on hand

# Debt Capacity

In addition to current 15% leverage

40%+

Target LTV on Acquisitions

### **Investment Avenues:**



- Holding level M&A
- Bolt-on acquisitions
- Portfolio company M&A

Above private equity return profile



Historically ticket sizes have averaged c.AED 0.4 BN with CMRC the largest to date at c.AED 0.9 BN

## 2021

Record year for capital deployment

## **AED 1.7 BN**

in transactions

### **AED 0.9 BN**

Deployed

### 2022

HDC & LIWA acquisitions

## 2. Driving portfolio growth & scale


Unmatched combination of industry expertise, and strategic planning & execution capabilities, with access to affordable capital enables portfolio value maximization

## **Platform Development**

Platform development supports superior returns, with valuations in excess of book value and the sum of individual assets and cross asset synergies

## **Corporate Governance**

Corporate governance best practices implemented across portfolio companies to ensure readiness for IPO or other strategic exits



## **Corporate Finance**

Capital structure optimisation and access to competitive financing, enables portfolio companies to pursue growth opportunities

## **Corporate Strategy**

Deep strategic planning and execution capabilities enables Amanat to unlock untapped potential of its portfolio by identifying strategic growth opportunities

## Successfully developing market leaders



**Abu Dhabi University** (part of NEMA Holding) ranked in UAE's top 10 universities



Middlesex University Dubai ranked highest KHDA Institution for enrolments in 21/22' with a 5-star rating from KHDA & QS






Cambridge Medical and Rehabilitation Center and Sukoon are two of the leading providers of post-acute, long-term care and rehabilitation in the GCC with 386 operational beds and a further 270 beds under development

## 3. Valuation growth through strong financial performance

Strong financial performance with record underlying performance in FY 2022 following overall record result in FY 2021, validating value creation model and turnaround strategy implemented in 2020.



<sup>(1)</sup> Total Income and Net Profit includes the share of income from subsidiaries & associates and finance lease income from NLCS, after PPA, excluding NCI. (2) Adjusted Net Profit excludes the gain on disposal and trading results from divested investees, one off non-recurring gain or loss, and transaction costs.

## Highly experienced board and senior leadership team

Talented management team with a solid track record regionally and internationally overseen by Board of Directors comprised of reputed professionals from the region

### **Board of Directors (more details in appendix B)**

Since — 2017 — 2020 — 2017 — 2019 — 2020 — 2020 — 2022 —



Mr. Hamad Alshamsi

Chairman



Dr. Ali Aldhaheri

Vice Chairman



Mr. Hamad Alnuaimi

Non-Executive Board Member



Mrs. Sara Nooruddin

Non-Executive Board Member



Mrs. Elham Al Qasim

Non-Executive Board Member



Mr. Dhafer Al Ahbabi

Non-Executive Board Member



Mr. Khalaf Sultan Al Dhaheri

Non-Executive Board Member

### **Executive Management (more details in appendix B)**

Since - 2021 ------- 2018 ------- 2015 ------- 2022 --------- 2019 ------- 2021 -----



John
Ireland
Acting Chief
Executive Officer Chief Financial
Officer



Amer Jeambey

Head of Healthcare Investments



Fadi Habib

Head of Education Investments



Abdulrahman Al Suwaidi

Investor Relations Director



**Anas Al Masri** 

Finance Director



Celine Schreiber

People Champion

# Investment case study: Human Development Company

**Beneficiaries** 

ciaries Centers

22

**Schools** 

**Financial** 

Overview

**Initial Consideration** 

**SAR 220 MN (60%)** 

> 3,000

Investment

Thesis

Education

 Market leader in an underserved sector with strong underlying growth drivers. 20k beneficiaries to date

Synergies with Amanat's healthcare and education platforms

 Scalable business through a tech-enabled standardized approach to delivery and asset light operating model

Clear growth strategy:

- Opening new branches in Saudi Arabia;
- o Introduction of new service lines; and
- o Potential footprint expansion to wider GCC region

 Opportunity to enhance quality and access in a sector that caters to a vulnerable segment of the population 9

**SAR 220 MN initial consideration,** potentially rising by SAR 47 MN, dependent on financial performance

10-11x implied 2021 EBITDA / EV multiple (initial consideration)

consideration)

2021 Revenue: SAR 86.7MN (+30% yoy)
 2021 EBITDA: SAR 38.6 MN (+96% yoy)

**2021 EBITDA Margin:** 44.5%

• **2021 Net Profit:** SAR 32.8 MN (+135% yoy)

• **2021 Net Profit Margin:** 38%

• **2021 Net Debt:** SAR 19.0 MN




Vocational / K-12





SEN Schools

Day Care Centers



**Human Development Company** 



Inpatient Rehabilitation



Post-Acute Care



Post-acute care portfolio companies





The acquisition of HDC on 27 October 2022 completes Amanat's continuum of childcare services in healthcare and education

Healthcare

# Investment case study: **Taaleem**



Taaleem is one of the largest providers of early learning, primary and secondary education in the UAE



## Investment case study: Middlesex University Dubai



















## Established and listed on the DFM in November 2014

#### March

Amanat concluded the acquisition of 35% in NEMA (previously ADUHC) (3) for AED 329.7 MN

Amanat shareholders approved 1.727% dividend at the Company's Annual General Meeting

#### June

Amanat acquired the real estate assets of North London Collegiate School Dubai for AED 375 MN

#### August

2018

Amanat acquired a 100% stake in Middlesex University DXB for a consideration of AED 419 MN

Amanat acquired a 69.3% stake in Malaki Specialist Hospital in Bahrain for AED 142.1 MN

#### February

Amanat's shareholders approved distribution of AED 2.2 fils per share cash dividend at the Company's Annual General Meeting

#### October

Amanat acquired a c.2% stake in BEGiN a US-based EdTech Company for AED 18.4 MN

#### March

Amanat shareholders approved dividend payout of AED 150 million, equating to AED 6 fils per share or 53% of profit attributable to equity shareholders

#### May

Amanat recognized as the number 1 listed company in the GCC in the Finance and Investment category among 700 companies by TopCEO.

NEMA Holding completes acquisition of 100% of LCT<sup>(1)</sup>, its second deal of the academic year following the acquisition of the remaining 49% of KHC<sup>(2)</sup> earlier in the year.

#### July

CMRC announced ground-breaking for a new building extension within its hospital in Al Ain

#### October

Amanat concluded the acquisition of 60% of Human Development Company for initial consideration of AED 216 MN

#### December

Amanat announced the merger of Cambridge Medical and Rehabilitation Center and Sukoon, creating the largest Pan-GCC Post-Acute Care Provider

#### 2015

2016

Annual General Meeting

Amanat invested a further AED 16.3

Amanat acquired 16.34% in Taaleem

Amanat shareholders approved 1.5%

Holdings PSC for AED 145.8 MN

dividend at the Company's first

MN in Sukoon through a capital

February

increase

April

### 2017

2019

#### 2020

2021

### 2022

#### 2023

#### May

Amanat acquired 4.14% stake in Al Noor Hospitals Group

#### August

Amanat acquired 35% stake in Sukoon International Holding Company CJSC

#### December

Amanat sold stake in Al Noor Hospitals Group

#### January

Amanat completed the acquisition of a 13.18% stake in International Medical Center for AED 360 MN

#### Apri

Amanat shareholders approved 1.5% dividend at the Company's Annual General Meeting

#### December

Amanat increased its stake in Taaleem Holdings PSC to 21.7%

#### March

Amanat shareholders approve AED 1.5 fils per share dividend at the Company's Annual General Meeting

#### July

Amanat led bolt-on acquisition for 3 medical clinics in Jeddah for IMC

#### October

Amanat invested an additional AED 33 MN in the NLCS expansion to increase its student capacity

#### February

Amanat acquires Cambridge Medical and Rehabilitation Center for AED 873 MN

#### April

Amanat divests its 21.7% in Taaleem Holdings for AED 350 MN

#### September

Amanat acquires Cambridge Medical and Rehabilitation Center Abu Dhabi Real Estate for AED 53 MN

Amanat divests its remaining 13.13% in International Medical Center for AED 433 MN

#### April

Amanat launched Amanat Healthcare Amanat's shareholders approved Share Buyback Program of up to 5% of outstanding shares and AED 100 Mn Dividend for 2022 (AED 4 fils per share)

Amanat completed the merger of Cambridge Medical and Rehabilitation Center and Sukoon, creating the largest Pan-GCC Post-Acute Care Provider



## **Board of Directors**

Wealth of business experience that spans more than

• CEO of a private investment company specializing in

Chairman and board member of several government

and private entities, including Dubai Islamic Bank, and

large scale real estate development projects;



Highlights

Mr. Hamad Alshamsi Chairman



**Dr. Ali Aldhaheri** Vice Chairman



- Over two decades of experience in establishing and launching successful ventures in various industries;
- CEO and Founder of NEMA Holding and Managing Director of Bin Harmal Group;
- Chairman and board member of several government and private entities, including Emirates International Hospital, Magna Investment and Al Ramz Corporation.



Mr. Hamad Alnuaimi Non-Executive Board Member

#### Highlights

- Board member on numerous leading investment, real estate and public sector institutions.
- Managing Director of His Highness Sheikh Dhiab Bin Zayed Al Nahyan's Office and His Highness Sheikh Nahyan Bin Zayed Al Nahyan's Office.
- Executive Director of Ministry of Presidential Affairs and serves as the Chairman of Electronic Stock and Brokerage Co. and the Managing Director at Reem Investments.



**Kuwait Food Company** 

Mrs. Sara Nooruddin Non-Executive Board Member

#### Highlights

- Head of Private Investments at Osool Asset Management;
- Serves on the board of a London-based Real Estate company, Aegila Capital Management;
- Previously served on the Board of Gulf Medical and Diabetes Center.



Mrs. Elham
Qasim
Non-Executive
Board Member

#### Highlights

- Chief Strategy and Technology Officer at Majid Al-Futtaim
- · Previously CEO of Digital 14;
- Serves on the boards of International Holding Company and the Khalifa Fund;
- Previously served as CEO of Abu Dhabi Investment Office (ADIO) and Director of Mubadala Investment Company;
- Previously served on the executive leadership team of Emirates Global Aluminum



#### Highlights

- An accomplished executive, investor, and entrepreneur with over 25 years experience in managing Investment and real estate;
- Chairman of Al Ramz Corporation;
- Founder & Chairman of Hameem Investments.



Mr. Khalaf Sultan Al Dhaheri Non-Executive Board Member

#### Highlights

- Chairman of Abu Dhabi National Islamic Finance and of Abu Dhabi National Properties Co.
- Also sits on the board of Abu Dhabi National Hotels, Al Masraf Arab Bank for Investment & Foreign Trade, Dar Al Takaful PJSC and Islamic Development Bank.
- Previously served as the Chairman of Massar Solutions PJSC.

## **Executive Management**



John Ireland
Acting Chief Executive
Officer Chief Financial Officer

#### Highlights

Prior to joining Amanat in September 2021, John held senior finance, strategy, and business development roles across a variety of industries including real estate, media and entertainment. He holds a Bachelor of Arts in Business Management from the University of Exeter and is a Qualified Chartered Accountant.



**Anas Al Masri** Finance Director

#### **Highlights**

Prior to joining Amanat Holdings in May 2019, Anas served as a Regional Finance Director at a regionally based international publicly listed company, with a focus on developing and managing a high functioning finance department in six different countries. he holds a Bachelor of Accounting. He is a certified Financial Controller and is well trained and highly knowledgeable in IFRS.



Amer Jeambey Head of Healthcare Investments

#### Highlights

Prior to joining Amanat in April 2018, Amer spent over a decade gaining investment experience with institutions such as Booz & Company, CPC Africa and Ithmar Capital Partners. He holds a Masters in Financial Economics from the American University in Beirut and an MBA from Columbia University.



Fadi Habib Head of Education Investments

#### Highlights

Prior to joining Amanat in April 2015, Fadi was Senior Associate in Equity Research at Scotiabank Global Banking & Markets in Toronto, covering publicly-listed Canadian banks and insurance companies for institutional investors. Fadi is a CFA charter holder, and holds a BSc in Engineering, with Honors, from Queen's University in Canada and an MBA from McMaster University in Canada.



Abdulrahman
Al Suwaidi
Investor Relations Director

#### Highlights

Prior to joining Amanat in November 2022, Abdulrahman held senior investments and investor relations positions at Dubai Holding, DXB Entertainments and the Dubai Financial Market (DFM). At the DFM he was involved in creating a stakeholder engagement platform that resulted in various new listings and initial public offerings. He holds a Bachelors Degree in International Business from the University of Colorado in the United States.



**Celine Schreiber**People Champion

#### Highlights

Prior to joining Amanat in September 2021, Celine led the Programs and Research Team at the Pearl Initiative and started her career as an M&A consultant within EY's Transaction Advisory, with a focus on sell-side transactions in retail and healthcare sectors. She holds an MBA from IE Business School in Spain and a master's degree from Vienna University of Business Administration in Austria University.



# **Analyst Coverage Report**



Company Update
April 27 2023



**Christine Kalindjian, CFA** 

Arqaam Capital Research

christine.kalindjian@arqaamcapital.com

## Target share price

**AED 1.30** 

Year-end (local m)	2022	<b>2023</b> e	<b>2024</b> e	<b>2025</b> e
Revenues	162	204	234	253
Net income	114	146	179	200
Net income (adj)	117	153	187	209
EPS	0.05	0.06	0.07	0.08
P/E (current price)	20.5	16.0	13.0	11.6
BVPS	1.1	1.1	1.2	1.2
P/B (current price)	0.86	0.82	0.78	0.75
Div. yield (%)	4.3	4.4	5.4	6.0
RoAA (%)	3.5	4.4	5.3	5.7
RoAE (%)	4.1	5.3	6.2	6.6
RoIC (%)	3.7	4.5	5.4	5.9





AED MN	1Q - 22	1Q - 23	Change
Middlesex University Dubai	16.5	19.1	16%
NEMA Holding	7.9	2.9	(64)%
North London Collegiate School - Real Estate	8.3	8.3	(0)%
Human Development Company	0.0	10.0	100%
Education Platform Income	32.7	40.3	23%
Cambridge Medical and Rehabilitation Centre	15.8	19.4	23%
Cambridge Medical and Rehabilitation Centre - Real Estate	0.3	1.0	>100%
Sukoon International Holding Company	0.3	0.5	100%
Malaki Specialist Hospital (2)	(2.5)	(2.9)	(18)%
Healthcare Platform Income	13.9	18.0	30%
Total Platform Income	46.6	58.3	25%
Other Income	0.6	0.6	3%
Interest and Investment Income	2.6	4.1	54%
Non-Recurring Income	0.0	0.3	100%
Purchase Price Amortisation	(2.9)	(3.5)	(22)%
Total Income	47.0	59.9	27%
HQ Costs	(10.7)	(11.7)	(9)%
Portfolio Management Costs	(0.4)	(0.5)	(31)%
Finance Charges <sup>(2)</sup>	(3.6)	(7.2)	(100)%
Transaction Related Costs	(0.1)	(0.4)	(100)%
Transaction Related Costs (associates)	(0.2)	0.0	100%
Non-Recurring Expense	0.0	(0.4)	(100)%
Net Profit	32.0	39.7	24%
Adjusted Net Profit <sup>(1)</sup>	32.3	40.1	24%

<sup>(1)</sup> For a reconciliation of adjusted measures please refer to other financial information (2) Includes Finance costs in relation to Malaki Specialist Hospital



# Financial Performance | Detailed profit and loss by quarter

AED MN	1Q - 22	2Q - 22	3Q - 22	4Q - 22	FY 22	1Q - 23
Middlesex University Dubai	16.5	18.5	(13.6)	15.8	37.3	19.1
NEMA Holding	7.9	9.8	(7.7)	18.5	28.6	2.9
North London Collegiate School - Real Estate	8.3	8.4	8.5	8.5	33.7	8.3
Human Development Company	0.0	0.0	0.0	7.3	7.3	10.0
Education Platform Income	32.7	36.8	(12.7)	50.2	107.0	40.3
Cambridge Medical and Rehabilitation Centre	15.8	15.4	20.6	21.8	73.6	19.4
Cambridge Medical and Rehabilitation Centre - Real Estate	0.3	0.4	0.4	2.8	3.9	1.0
Sukoon International Holding Company	0.3	0.4	0.3	0.2	1.2	0.5
Malaki Specialist Hospital (2)	(2.5)	(2.8)	(2.8)	(3.5)	(11.5)	(2.9)
Healthcare Platform Income	13.9	13.5	18.6	21.3	67.2	18.0
Total Platform Income	46.6	50.2	5.8	71.5	174.2	58.3
Gain on Disposal	0.0	0.0	0.0	0.0	0.0	0.0
Share of Prior Period Trading Result	0.0	0.0	0.0	0.0	0.0	0.0
Other Income	0.6	0.7	0.6	0.6	2.6	0.6
Interest and Investment Income	2.6	3.4	4.3	3.1	13.5	4.1
Non-Recurring Income	0.0	0.0	0.0	3.6	3.6	0.3
Purchase Price Amortisation	(2.9)	(2.9)	(2.9)	(3.4)	(12.1)	(3.5)
Total Income	47.0	51.5	7.9	75.4	181.8	59.9
HQ Costs	(10.7)	(10.7)	(10.5)	(9.5)	(41.4)	(11.7)
Portfolio Management Costs	(0.4)	0.0	(0.5)	(0.3)	(1.2)	(0.5)
Finance Charges <sup>(2)</sup>	(3.6)	(3.9)	(5.3)	(5.4)	(18.2)	(7.2)
Transaction Related Costs	(0.1)	(0.7)	(2.1)	(2.4)	(5.3)	(0.4)
Transaction Related Costs (associates)	(0.2)	(1.5)	0.0	0.0	(1.7)	0.0
Non-Recurring Expense	0.0	0.0	0.0	0.2	0.2	(0.4)
Net Profit	32.0	34.6	(10.4)	58.0	114.2	39.7
Adjusted Net Profit (1)	32.3	36.9	(8.3)	56.6	117.4	40.1

<sup>(1)</sup> For a reconciliation of adjusted measures please refer to other financial information (2) Includes Finance costs in relation to Malaki Specialist Hospital



## Financial Position | Standalone balance sheet

AED MN	Dec22	Mar23	Change
Middlesex University Dubai	405	423	18
NEMA Holding	385	387	2
North London Collegiate School - Real Estate	415	414	(1)
Human Development Company	267	276	9
Education Platform Investments	1,472	1,500	29
Cambridge Medical and Rehabilitation Centre	982	999	17
Cambridge Medical and Rehabilitation Centre - RE	50	49	(1)
Sukoon International Holding Company	131	131	0
Malaki Specialist Hospital	42	38	(5)
Healthcare Platform Investments	1,205	1,218	12
Begin	19	19	0
Other Non-Current assets	69	70	0
Total Non-Current Assets	2,765	2,806	41
Cash and Bank Balances	433	470	37
Other Currents Assets	25	26	1
Total Current Assets	458	496	38
Total Assets	3,222	3,302	79
Share Capital, Premium and Statutory Reserves	2,538	2,563	26
Fair Value Reserve	(24)	(24)	0
Other Reserve	(18)	(18)	(0)
Retained Earnings	216	255	40
Total Equity Attributable To The Owners Of The Company	2,712	2,777	65
Bank Borrowings	336	326	(10)
Other Non-Current Liabilities	39	10	(29)
Total Non-Current Liabilities	375	336	(39)
Other Current Liabilities	136	189	53
Total Current Liabilities	136	189	53
Total Liabilities	511	525	14
Total Equity And Liabilities	3,222	3,302	79

### **Key Highlights**

AED 65 MN increase in net assets mainly driven by:

- Increase in cash balances of AED 37 MN from increase in cash balances (AED 25 MN) held by third party liquidity provider, NLCS rental collections (AED 9.6 MN) and other working capital movements
- Increase in non-current assets (AED 41 MN) mainly driven by:
  - Platform Income (AED 54.8 MN after PPA)
  - Offset by NLCS rental receipts (-AED 9.6 MN)
- Decrease in bank borrowings (AED 10 MN) due to scheduled quarterly amortization related to acquisition finance associated with the CMRC acquisition
- Increase in other current liabilities (AED 53 MN)
  mainly from reclassification of HDC related deferred
  contingent consideration from other non-current to
  current liabilities



## Financial Position | Consolidated group balance sheet

AED MN	Dec22	Mar23	Change
Property and equipment	272	277	5
Right-of-use assets	176	188	12
Goodwill and intangible assets	1,420	1,418	(2)
Investments in associates	516	518	3
Finance lease receivables	363	370	7
Financial assets at fair value through OCI	32	32	0
Other financial asset	5	5	0
Total Non-Current Assets	2,783	2,808	25
Cash and bank balances	584	654	70
Finance lease receivables	52	44	(8)
Other current assets	212	237	25
Total Current Assets	848	935	87
TOTAL ASSETS	3,631	3,743	112
Share capital, premium and statutory reserves	2,520	2,545	25
Cash flow hedge reserve	0	0	0
Fair value reserve of financial assets at FVOCI	(24)	(24)	0
Retained earnings	216	256	40
Total Equity Attributable to the Owners of the Company	2,712	2,777	65
Non-controlling interests	34	39	5
Total Equity	2,746	2,816	70
Bank financing	356	344	(12)
Lease liabilities	163	178	14
Other long-term payables	33	4	(30)
Other long-term liabilities	39	41	2
Total Non-Current Liabilities	592	566	(25)
Bank overdraft	12	17	5
Bank financing	69	74	5
Accounts and other payables	138	172	34
Lease liabilities	27	25	(2)
Other current liabilities	47	73	26
Total Current Liabilities	293	360	67
Total Liabilities	885	927	42
TOTAL EQUITY AND LIABILITIES	3,631	3,743	112

#### **Key Highlights**

- Increase in PPE of AED 5 MN driven by asset additions of AED 11.5 MN primarily from the CMRC bed expansion (Al Ain) and HDC expansions partly offset by AED (6.6) MN of depreciation
- Increase in ROU assets of AED 12 MN mainly driven by an addition of a new lease agreement in CMRC (Khobar expansion facility) of AED 18.4 MN, partly offset by AED (6.4) MN of depreciation
- Increase in investments in associates of AED 3 MN from share of profit from associates offset by PPA amortization (AED 0.8 MN)
- Increase in cash and bank balance of AED 70 MN from subsequent receivable collections at HDC (AED 33 MN), increase in cash held by liquidity provider (AED 25 MN), NLCS rental collections (AED 9.6 MN) and other working capital movements across the Group
- Increase in other current assets of AED 25 MN mainly from receivables at HDC & CMRC related to student fee and insurance provider
- Net decrease of bank financing and overdraft facility balances of AED (2.2) MN due to scheduled repayments on the CMRC loan of AED (10.1) MN and HSBC financing of AED (1.5) MN partly offset by drawdown of overdraft facility at MSH of AED 5.0 MN and working capital facility at HDC of AED 4.0 MN
- Increase in other current liabilities of AED 26 MN mainly due to higher student deposits at MDX resulting from a higher student intake for AY22//23

# Statutory to adjusted total income & net profit reconciliation

FY19	FY20	FY21	FY22	1Q - 22	2Q - 22	3Q - 22	4Q - 22	FY 22	1Q - 23
111.7	74.2	371.0	181.8	47.0	51.5	7.9	75.4	181.8	59.9
0.0	16.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
(20.1)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
0.0	0.0	(202.9)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
(28.7)	(11.4)	(14.5)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
0.0	0.0	0.0	(3.6)	0.0	0.0	0.0	(3.6)	(3.6)	(0.3)
(48.9)	5.4	(217.4)	(3.6)	0.0	0.0	0.0	(3.6)	(3.6)	(0.3)
62.8	79.6	153.7	178.2	47.0	51.5	7.9	71.8	178.2	59.5
	0.0 (20.1) 0.0 (28.7) 0.0 (48.9)	0.0 16.8 (20.1) 0.0 0.0 (28.7) (11.4) 0.0 0.0 (48.9) 5.4	111.7     74.2     371.0       0.0     16.8     0.0       (20.1)     0.0     0.0       0.0     0.0     (202.9)       (28.7)     (11.4)     (14.5)       0.0     0.0     0.0       (48.9)     5.4     (217.4)	111.7     74.2     371.0     181.8       0.0     16.8     0.0     0.0       (20.1)     0.0     0.0     0.0       0.0     0.0     (202.9)     0.0       (28.7)     (11.4)     (14.5)     0.0       0.0     0.0     0.0     (3.6)       (48.9)     5.4     (217.4)     (3.6)	111.7     74.2     371.0     181.8     47.0       0.0     16.8     0.0     0.0     0.0       (20.1)     0.0     0.0     0.0     0.0       0.0     0.0     (202.9)     0.0     0.0       (28.7)     (11.4)     (14.5)     0.0     0.0       0.0     0.0     0.0     (3.6)     0.0       (48.9)     5.4     (217.4)     (3.6)     0.0	111.7     74.2     371.0     181.8     47.0     51.5       0.0     16.8     0.0     0.0     0.0     0.0       (20.1)     0.0     0.0     0.0     0.0     0.0       0.0     0.0     (202.9)     0.0     0.0     0.0       (28.7)     (11.4)     (14.5)     0.0     0.0     0.0       0.0     0.0     0.0     0.0     0.0       (48.9)     5.4     (217.4)     (3.6)     0.0     0.0	111.7       74.2       371.0       181.8       47.0       51.5       7.9         0.0       16.8       0.0       0.0       0.0       0.0       0.0         (20.1)       0.0       0.0       0.0       0.0       0.0       0.0         0.0       0.0       (202.9)       0.0       0.0       0.0       0.0         (28.7)       (11.4)       (14.5)       0.0       0.0       0.0       0.0         0.0       0.0       0.0       0.0       0.0       0.0         (48.9)       5.4       (217.4)       (3.6)       0.0       0.0       0.0	111.7       74.2       371.0       181.8       47.0       51.5       7.9       75.4         0.0       16.8       0.0       0.0       0.0       0.0       0.0       0.0       0.0         (20.1)       0.0       0.0       0.0       0.0       0.0       0.0       0.0       0.0         0.0       0.0       (202.9)       0.0       0.0       0.0       0.0       0.0       0.0         (28.7)       (11.4)       (14.5)       0.0       0.0       0.0       0.0       0.0       0.0         0.0       0.0       0.0       0.0       0.0       0.0       0.0       (3.6)         (48.9)       5.4       (217.4)       (3.6)       0.0       0.0       0.0       0.0       (3.6)	111.7       74.2       371.0       181.8       47.0       51.5       7.9       75.4       181.8         0.0       16.8       0.0       0.0       0.0       0.0       0.0       0.0       0.0         (20.1)       0.0       0.0       0.0       0.0       0.0       0.0       0.0       0.0         0.0       0.0       (202.9)       0.0       0.0       0.0       0.0       0.0       0.0       0.0         (28.7)       (11.4)       (14.5)       0.0       0.0       0.0       0.0       0.0       0.0       0.0       0.0         0.0       0.0       0.0       0.0       0.0       0.0       0.0       0.0       0.0       0.0         (48.9)       5.4       (217.4)       (3.6)       0.0       0.0       0.0       0.0       (3.6)       (3.6)

AED MN	FY19	FY20	FY21	FY22	1Q - 22	2Q - 22	3Q - 22	4Q - 22	FY 22	1Q - 23
Net Profit	60.0	10.1	280.8	114.2	32.0	34.6	(10.4)	58.0	114.2	39.7
Adjustments for:										
One-Time Receivable Provision at Sukoon	0.0	16.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gain on Contingent Consideration re Middlesex	(20.1)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gain on Disposal	0.0	0.0	(202.9)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Share of Prior Period Trading Result	(28.7)	(11.4)	(14.5)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Transaction Related Costs	3.4	10.5	20.0	5.3	0.1	0.7	2.1	2.4	5.3	0.4
Transaction Related Costs (associates)	0.0	0.0	0.0	1.7	0.2	1.5	0.0	0.0	1.7	0.0
Derivative Recognition	0.0	0.0	0.0	(3.6)	0.0	0.0	0.0	(3.6)	(3.6)	(0.3)
Other Movement	0.0	0.0	20.0	(0.2)	0.0	0.0	0.0	(0.2)	(0.2)	0.4
Total Adjustments	(45.5)	15.9	(177.5)	3.2	0.3	2.2	2.1	(1.4)	3.2	0.4
Adjusted Net Profit	14.6	26.0	103.4	117.4	32.3	36.9	(8.3)	56.6	117.4	40.1



Amanat assess the performance of the Group using a variety of alternative performance measures (APMs), including total income and net profit presented on both a "core" and an "adjusted basis". A summary of the statutory IFRS and alternative approaches is included below:

#### **Statutory IFRS**

- Control is achieved when the Group is exposed, or has rights to, variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee
- Non-controlling interests i.e. minority stakes are presented separately
  in equity in the consolidated statement of financial position and the
  results and total comprehensive income attributable to the NCI is
  disclosed in the consolidated statement of profit or loss and
  consolidated statement of other comprehensive income, respectively
- Investments in associates are accounted for using the equity method, associates being those entities where over a 20% stake is held and / or significant influence is exercised
- Under the equity method on initial recognition the investment is recognized at cost and then adjusted for the subsequent share of profit or loss and OCI of the investee. Distributions received reduce the carrying value
- Investments where there is no significant influence or control, generally where less than 20% stakes are held, are held at fair value

#### Alternative Performance Measures - Non IFRS

- Under the income and net profit approach the net profit of each investment where control or significant influence is exercised is proportionately consolidated e.g. AED 100 earned from a 35% investment would be recognized as net profit of AED 35
- Similarly AED 100 earned from a 75% investment would be recognized as net profit of AED 75
- Holding company revenues and expenses are recognized 100%
- A standalone income statement and balance sheet is presented to aid the understanding of the user
- Net profit attributable to equity holders of the parent and overall net profit is the same in both the statutory IFRS and APM measures



Amanat assesses the performance of the Group using a variety of alternative performance measures (APMs), including total and net profit presented on both a "core" and an "adjusted basis". A summary of the statutory IFRS and alternative approaches is included below:

AED MN	As per Statutory Financial Statements	Share of Net Income from Subsidiaries	Share of Net Income from Equity Investments	Net Income from Assets Held under Finance Lease	Reclass to Holding Income Statement	Interest and Finance Income/Cost Allocation	As Per APM
Statutory Financial Statements							
Revenue	185.2	(185.2)					0.0
Direct Costs	(93.4)	93.4					0.0
Gross Profit	91.8	(91.8)	0.0	0.0	0.0	0.0	0.0
General and Administrative Expenses	(55.0)	42.4			12.6		0.0
Other Operating Income	4.2	(3.6)			(0.6)		0.0
Share of results of associates	2.6		(2.6)				0.0
Income from finance lease	8.3			(8.3)			0.0
Operating Profit / (Loss)	51.9	(52.9)	(2.6)	(8.3)	11.9	0.0	0.0
Finance Income	4.5	(0.4)				(4.1)	0.0
Finance Costs	(11.0)	3.8				7.2	0.0
Income tax / Zakat Expenses	(1.0)	1.0					0.0
NCI	(4.7)	4.7					0.0
APM Financial Statements							
Middlesex University Dubai		19.1					19.1
NEMA Holding			2.9				2.9
Human Development Company		10.0					10.0
North London Collegiate School - Real Estate				8.3			8.3
Cambridge Medical and Rehabilitation Centre		19.4					19.4
Cambridge Medical and Rehabilitation Centre - Real Estate		1.0					1.0
Sukoon International Holding Company			0.5				0.5
Malaki Specialist Hospital		(2.9)					(2.9)
Purchase Price Amortisation		(2.7)	(8.0)				(3.5)
Finance Income						4.1	4.1
Other Income					0.6		0.6
Holding Level Costs					(12.2)		(12.2)
Transaction Related Costs					(0.4)		(0.4)
Transaction Related Costs (associates)							0.0
Non-recurring Items					(0.0)		(0.0)
Finance Costs						(7.2)	(7.2)
Profit for the Period	39.7	(0.0)	0.0	0.0	0.0	0.0	39.7

## Contacts

### Abdulrahman Al Suwaidi

**Investor Relations Director** investor.relations@amanat.com

### Claudia Madfouni

Marketing Analyst Corporate.communications@amanat.com



Stay Connected









amanat.com